Pembrolizumab in the treatment of patients with non-small cell lung cancer and metastatic brain lesion: a clinical review

Background. This article presents a clinical case describing the own authors’ experience of the effective use of pembrolizumab in a patient with non-small cell lung cancer (NSCLC) with metastatic brain lesion. Description of the clinical case. A patient with peripheral cancer of the right lung T3N3M1 (stage IV), metastasis to the left parietal region, the condition after removal of metastasis in the left parietal region and the treatment with pembrolizumab. The size of the tumor foci according to computed tomography of the chest before treatment: the tumor node size at the S1/S2 border was 20x20 mm, aortopulmonary lymph node - 17x15 mm, bronchopulmonary lymph node - 15x15 mm. According to the results of the control examination at 12th week therapy with pembrolizumab, partial regression of the tumor was achieved. According to this CT scan of the chest: tumor node size at the border S1/S2 - 10x9 mm, aortopulmonary lymph node - 10x5 mm, bronchopulmonary lymph node - 10x12 mm. At the time of the description of the clinical case (October 2019), therapy with pembrolizumab is continued, partial regression remains. During therapy, adverse reactions were not observed. Conclusion. The results allow to conclude that therapy with pembrolizumab is the effective and safe options for the treatment of patients with NSCLC and brain metastasis.

non-small cell lung cancer, brain lesion, pembrolizumab, clinical case